This Solicitation opportunity from Department Of Defense was posted on June 8, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
BUPIVACAINE HYDROCH
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The contract solicitation is for Bupivacaine Hydrochloride, identified by NSN 6505-00-138-7347, with a requested quantity of three units under Purchase Request 7017074053. Issued by the Defense Logistics Agency under the Department of Defense, the solicitation number is SPE2DP-26-T-3759 and was posted on June 8, 2026, with a response deadline of June 15, 2026. The North American Industry Classification System code 424210 indicates the procurement falls under wholesale trade of pharmaceuticals and pharmacy supplies. The solicitation is open to federal entities with no specific set-aside designation, and the place of performance and point of contact details are not provided. All responses must be submitted through the DIBBS platform via the provided online link.
General Info
Agency
NAICS
Place of Performance
USASet-Aside
Documents
(1)AI Contract Breakdown
Uniform Contract FormatWhat is UCF?
Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.
Timeline
Submission Closed
Organization & Contact Information
Full Description
More opportunities from Department Of Defense → Defense Logistics Agency
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
